Abstracts tagged "cytokines"

Abstract Number: 1438 • ACR Convergence 2021
Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions
Renan Vergara¹, Alex Chen¹, Jerry Chen¹, Marianne Riley¹, Luis Blancas-Mejia¹, Christie Mortales¹, Tania Berrocal¹, Tanu Priya¹, Marsha Mason¹, Kevin Yu¹, Olga Sharapova¹, Jorgen Nelson¹, Alfredo Quijano-Rubio¹, Thomas Linsky¹, Ryan Swanson¹ and Daniel-Adriano Silva², ¹Neoleukin Therapeutics, Inc., Seattle, WA, ²Formerly of Neoleukin Therapeutics, Inc., Seattle, WA
Background/Purpose: T cell mediated pathology is central to many forms of autoimmunity, and cytokines perform critical inflammatory functions during this process. IL-2 and IL-15 are…
Abstract Number: 0512 • ACR Convergence 2021
Peficitinib and Filgotinib Inhibit Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari, Takeo Isozaki, Kuninobu Wakabayashi and Tsuyoshi Kasama, Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Peficitinib and filgotinib are novel Janus kinase (JAK) inhibitors developed for the treatment of rheumatoid arthritis (RA). Peficitinib inhibits all JAKs, especially JAK3. Filgotinib,…
Abstract Number: 1455 • ACR Convergence 2021
IL1β mRNA Expressions in Peripheral Blood Mononuclear Cells Increase and May Associate with Cartilage Damage of the Respiratory Tract Probably Through Matrix metalloproteinase-3 Production in Patients with Relapsing Polychondritis
Jun Shimizu¹, Sueshige Wakisaka¹, Tomoko Suzuki¹ and Noboru Suzuki², ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²St. Marianna University School of Medicine, Kawasaki Kanagawa, Japan
Background/Purpose: Relapsing polychondritis (RP) is an inflammatory disorder that affects cartilage of ears, nose, joints, and respiratory tract. The inflammation often spreads to eyes, cardiovascular…
Abstract Number: 0535 • ACR Convergence 2021
Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
Priyal Dave¹, Tiange Dong¹, Andrew Mead¹, Isaac Asante¹, Brandon Ebright¹, Eugene Zhou¹, RIta Li¹, Nicos Petasis¹, William Stohl² and Stan Louie¹, ¹University of Southern California, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Neutrophils are key initiators and promoters of autoimmunity, including SLE, via the elaboration of neutrophil extracellular traps (NETs). We tested the efficacy of the…
Abstract Number: 1472 • ACR Convergence 2021
Characterization and Function of Tumor Necrosis Factor α and Interleukin-6–Induced Osteoclasts in Rheumatoid Arthritis
Kazuhiro Yokota¹, Kojiro Sato², Yoshimi Aizaki³, Shinya Tanaka⁴, Miyoko Sekikawa⁴, Noritsune Kozu⁵, Yuho Kadono⁴, Hiromi Oda⁶ and Toshihide Mimura⁷, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Jichi Medical University, Tochigi, Japan, ³Saitama Medical University, Saitama, Japan, ⁴Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan, ⁵Kozu Orthopaedic Clinic, Chiba, Japan, ⁶Department of Orthopaedic Surgery, National Hospital Organization Ibusuki Medical Center, Kagoshima, Japan, ⁷Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama, Japan
Background/Purpose: We have previously reported that stimulation of mouse bone marrow–derived macrophages with a combination of tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) induces…
Abstract Number: 0572 • ACR Convergence 2021
Circulating Cytokines and Chemokines Are Associated with the Risk of Incident Cardiovascular Disease in Rheumatoid Arthritis Independent of Conventional Disease Activity Measures
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Joshua Baker³, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in rheumatoid arthritis (RA). While chronic inflammation contributes to CVD pathogenesis, the role of specific…
Abstract Number: 1509 • ACR Convergence 2021
Pharmacological Inhibition of MALT1 Reverses Activation-Induced Metabolic Reprogramming and Ameliorates Autoimmune Pathogenesis in Multiple Animal Models of Chronic Inflammation
Subhabrata Biswas, Mya Steadman, Ynes Helou, Katherine Sellers, Keng Soh, Aditi Chalishazar, Mehmet Badur, Joanna DiSpirito, Brian DeChristopher, John Monroe, Dania Rabah, Barbara Fox and Andy Long, Rheos Medicines, Inc, Cambridge, MA
Background/Purpose: Current therapies for autoimmune and inflammatory diseases generally target select disease nodes, often failing to produce durable clinical remission. Chronic inflammation is associated with…
Abstract Number: 0722 • ACR Convergence 2021
Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity
Alexandrine Mahoudeau¹, Céline Anquetil², Nozomu Tawara¹, Hossein Khademian¹, Damien Amelin¹, Yves Allenbach³ and Olivier Benveniste³, ¹Center of Research in Myology, Sorbonne University, Paris, France, ²Center of Research in Myology, Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France
Background/Purpose: In Idiopathic Inflammatory Myopathies (IIM) disease activity is very difficult to assess and IIM may induce severe muscle damage, especially in immune-mediated necrotizing myopathies…
Abstract Number: 1531 • ACR Convergence 2021
New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19
Sarah Chang¹, Allan Feng¹, Wenzhao Meng², Sokratis Apostolidis², Elisabeth Mack³, Maja Artandi¹, Linda Barman¹, Kate Bennett⁴, Saborni Chakraborty¹, Iris Chang¹, Peggie Cheung¹, Sharon Chinthrajah¹, Shaurya Dhingra¹, Evan Do¹, Amanda Finck⁴, Andrew Gaano⁴, Reinhard Gessner⁵, Heather Giannini⁴, Joyce Gonzalez⁴, Sarah Greib³, Margrit Gündisch³, Alex Hsu¹, Alex Kuo¹, Monali Manohar¹, Rong Mao¹, Indira Neeli⁶, Andreas Neubauer³, Oluwatosin Oniyide², Abigail Powell¹, Rajan Puri¹, Harald Renz³, Jeffrey Schapiro⁷, Payton Weidenbacher¹, Rich Wittman¹, Neera Ahuja¹, Ho-Ryun Chung³, Pras Jagannathan¹, Judith James⁸, Peter Kim¹, Nuala Meyer², Kari Nadeau¹, Marko Radic⁶, William Robinson⁹, Upinder Singh¹, Taia Wang¹, John Wherry⁴, Chrysanthi Skevaki³, Eline Luning Prak⁴ and Paul Utz¹⁰, ¹Stanford, San Francisco, ²University of Pennsylvania, Philadelphia, PA, ³Marburg University, Marburg, Germany, ⁴UPenn, Philadelphia, PA, ⁵University of Marburg, Marburg, Germany, ⁶UTHSC, Memphis, TN, ⁷KPNC Regional Laboratory, Berkeley, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Stanford University, Palo Alto, CA, ¹⁰Stanford University, Stanford, CA
Background/Purpose: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is associated with a wide range of clinical manifestations, including autoimmune features…
Abstract Number: 0867 • ACR Convergence 2021
A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus
Christopher Oliveira¹, Yenealem Temesgen-Oyelakin², Mohammad Naqi³, Nidhi Patel², Philip Parel², Massimo Gadina⁴, Stefania Dell'Orso², Stephen Brooks², Sarthak Gupta⁵, Nehal Mehta⁶, Sarfaraz Hasni³ and Mariana Kaplan³, ¹National Institutes of Health (NIH), Vienna, VA, ²National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁶NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with enhanced cardiovascular (CV) risk linked to both traditional Framingham risk factors and lupus-specific immune dysregulation. Characterizing an…
Abstract Number: 1577 • ACR Convergence 2021
Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout
Adela Navratilova¹, Veronika Voclonová², Hana Hulejová², Lucie Andrés Cerezo¹, Markéta Pavlíková³, Viktor Bečvář², Jakub Zavada¹, Karel Pavelka⁴, Ladislav Senolt⁴ and Blanka Stiburkova⁵, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: IL-37 is an anti-inflammatory cytokine, member of IL-1 family, related to inflammatory and autoimmune diseases. Here we aimed to investigate the association of genetic…
Abstract Number: 1000 • ACR Convergence 2021
Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages
Huaping Qin¹, Patricia Oliveira¹, Tiffany Yan¹, Robert Terkeltaub² and Ru Liu Bryan³, ¹University of California San Diego, La Jolla, CA, ²VA/UCSD, San Diego, CA, ³University of California San Diego and VASDHS, San Diego, CA
Background/Purpose: CD38 can function as a degrading enzyme of nicotinamide adenine dinucleotide (NAD), a critical metabolic intermediate serving as enzyme cofactor in redox reactions and…
Abstract Number: 1645 • ACR Convergence 2021
Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis
Joshua Baker¹, Bryant England², Michael George¹, Katherine Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Paul Monach⁶, Gary Kunkel⁷, Brian Sauer⁷, Bartlett Hamilton⁸, Carlos Hunter², Michael Duryee², Geoffrey Thiele² and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁶Brigham and Women's Hospital, Boston, MA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Nebraska, Omaha, NE
Background/Purpose: Adipokines are metabolic regulators and are associated with adverse outcomes in chronic conditions and among older adults. Elevations in one adipokine, adiponectin, have been…
Abstract Number: 1003 • ACR Convergence 2021
Significant Enrichment of Pathogenic CD206+CD163+ Macrophages in Rheumatoid Arthritis Synovial Tissue with Distinct Transcriptional Signatures
Megan Hanlon¹, Mary Canavan², Nuno Neto³, Qingxuan Song⁴, Phil Gallagher⁵, Ronan Mullan⁶, Conor Hurson⁷, Barry Moran³, Michael Monaghan³, Sunil Nagpal⁸, Douglas Veale⁹ and Ursula Fearon³, ¹Molecular Rheumatology, Dublin, Ireland, ²Trinity College, Santry, Ireland, ³Trinity College Dublin, Dublin, Ireland, ⁴Janssen Research & Development LLC, Spring House, PA, ⁵St Vincent's Hospital, Dublin, Ireland, ⁶Tallaght University Hospital, Dublin, Ireland, ⁷St Vincents University Hospital, Dublin, Ireland, ⁸Janssen Research, Collegeville, PA, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Synovial tissue macrophages are an exquisitely plastic pool of innate cells that play a key role in RA disease progression. However, the precise nature,…
Abstract Number: 1768 • ACR Convergence 2021
Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus Erythematosus with Stable Disease Activity
Risa Wakiya¹, Kiyo Ueeda¹, Hiromi Shimada¹, Shusaku Nakashima¹, Mikiya Kato¹, Taichi Miyagi², Mansour mai¹, Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹, Tomohiro Kameda¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: In systemic lupus erythematosus (SLE), atherosclerosis is strongly associated with vital prognosis. On the other hand, arteriosclerosis is strongly influenced by serum adipokines. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].